Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,117
  • Shares Outstanding, K 10,635
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,850 K
  • 60-Month Beta 2.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CNSP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.66
  • Most Recent Earnings $-0.95 on 04/01/24
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1900 +1.16%
on 04/17/24
0.3900 -50.72%
on 03/28/24
-0.1858 (-49.15%)
since 03/22/24
3-Month
0.1900 +1.16%
on 04/17/24
0.5800 -66.86%
on 01/24/24
-0.3698 (-65.80%)
since 01/23/24
52-Week
0.1900 +1.16%
on 04/17/24
2.9800 -93.55%
on 06/02/23
-1.6978 (-89.83%)
since 04/21/23

Most Recent Stories

More News
CNS Pharmaceuticals (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured...

CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals’ (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently...

CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released...

CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Board

With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage...

ROIV : 10.95 (+3.30%)
CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced...

CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed...

CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced...

CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals’ (NASDAQ: CNSP) Interim Analysis on Berubicin Trial Showing Promising Results

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the...

CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced...

CNSP : 0.2000 (+0.45%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today...

CNSP : 0.2000 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 0.2278
2nd Resistance Point 0.2188
1st Resistance Point 0.2090
Last Price 0.2000
1st Support Level 0.1902
2nd Support Level 0.1812
3rd Support Level 0.1714

See More

52-Week High 2.9800
Fibonacci 61.8% 1.9142
Fibonacci 50% 1.5850
Fibonacci 38.2% 1.2558
Last Price 0.2000
52-Week Low 0.1900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar